Yara Afaneh was scrolling through her phone on the platform at the Loyola CTA Red Line station Tuesday afternoon when a man approached and said “excuse me miss.” Afaneh, 23, didn’t look up, but when ...

A large genome-wide analysis reports that common obesity traits share, and in some cases drive, risk for diabetic kidney disease, diabetic retinopathy, and diabetic neuropathy. The study maps shared ...

Sept 29 (Reuters) - Metsera's (MTSR.O), opens new tab experimental obesity drug showed significant weight loss and favorable tolerability in two mid-stage studies, the drug developer said on Monday.

Seeing the “too many redirects” page pop up isn’t just a browser error, it’s also a silent SEO killer. Every time a URL sends a visitor or search engine crawler to another URL automatically—called a ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a deal to buy Metsera for an initial $4.9 billion to secure a pipeline of ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Pfizer, which has struggled in the race for new obesity drugs, said ...

VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn ...